Neonate RSV Passive Immunity

My Take: Good efficacy and fixed-dose (versus weight-based dosing) are both favorable

Name: Enflonsia (clesrovimab‑cfor)

Class: RSV F protein–directed fusion inhibitor (monoclonal antibody)

Usefulness: Passive immunization for neonates and infants entering their first RSV season to prevent lower respiratory‑tract disease

Method of action: Binds the RSV fusion (F) protein, blocking viral entry into host cells and preventing replication and infection in the respiratory tract .

Potential market: Infants born during or just before RSV season (~fall–spring); neonatal populations at high risk of severe RSV. In the U.S., over 3 million infants are born annually—many entering RSV season, making this a substantial preventive market.

Competing agents:

• nirsevimab (Beyfortus) – another long‑acting monoclonal antibody for RSV prophylaxis in infants.

• Palivizumab (Synagis) – older monoclonal antibody for high‑risk infants (e.g., prematurity, congenital heart disease).

Cost to consumer: Typically administered via healthcare provider; pricing not yet officially announced publicly. Similar products (e.g. Beyfortus) are estimated around $5,000 per dose. Expect a comparable upfront cost per RSV season.

Interesting facts:

• It received FDA approval on June 9, 2025, making it one of the latest additions to infant immunization options

• Unlike traditional vaccines, Enflonsia provides immediate passive immunity via antibody infusion, not active immunization.

• It’s given as a single dose timed to protect newborns through peak RSV risk months.